Solriamfetol study of brain chemicals and depression
About this title
Read the official source — NCT06360419Researchers compared Solriamfetol 300 mg and placebo to find out how the approaches affected depression symptoms in people with depression.
Understand this study
What did researchers investigate?
Researchers compared Solriamfetol 300 mg and placebo to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 39 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 346
- Sponsor
- Axsome Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06360419
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Trial of Solriamfetol in Subjects With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock · Bellflower · Encino
35 more locations
- Lemon Grove
- Los Angeles
- Montclair
- Oceanside
- Redlands
- Riverside
- Sherman Oaks
- Torrance
- Upland
- Walnut Creek
- Cromwell
- Brandon
- Hialeah
- Jacksonville
- Orlando
- Chicago
- Overland Park
- New Orleans
- Boston
- Saint Charles
- Las Vegas
- Brooklyn
- Rochester
- Staten Island
- Hickory
- Cincinnati
- Oklahoma City
- Media
- Philadelphia
- Memphis
- Austin
- Dallas
- Friendswood
- Wichita Falls
- Everett
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Solriamfetol 300 mg and placebo to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Axsome Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including Solriamfetol 300 mg and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
